Milkiewicz Piotr, Wunsch Ewa
Department of Hepatology and Liver Transplantation, M.Curie Hospital, Arkonska 4, 71-455 Szczecin, Poland.
Recent Results Cancer Res. 2011;185:117-33. doi: 10.1007/978-3-642-03503-6_7.
Primary sclerosing cholangitis (PSC) is a chronic liver condition which may affect both intra and extrahepatic biliary tree. Etiology of PSC remains to be fully elucidated but genetic, autoimmune, inflammatory and possibly infective factors could all contribute to its development. More than two-thirds of patients are males and the most commonly associated condition is an inflammatory bowel disease which occurs in up to 70% of affected subjects. Endoscopic cholangiopancreatography (ERCP) and magnetic resonanse cholangiopancreatography (MRCP) remain a gold standard in the diagnosis of this condition. No curative treatment of PSC exists and a proportion of patients who develop liver failure or suffer from recurrent episodes of cholangitis requires liver transplantation. PSC is associated with increased risk of malignancies, in particular cholangiocarcinoma which may arise in 12% of patients. The main aim of this chapter is to review the current knowledge on pathogenesis and clinical aspects of PSC as well as its associated malignancies.
原发性硬化性胆管炎(PSC)是一种慢性肝脏疾病,可累及肝内和肝外胆管树。PSC的病因仍有待充分阐明,但遗传、自身免疫、炎症以及可能的感染因素都可能促成其发展。超过三分之二的患者为男性,最常伴发的疾病是炎症性肠病,在高达70%的受累患者中出现。内镜逆行胰胆管造影(ERCP)和磁共振胰胆管造影(MRCP)仍然是诊断该病的金标准。目前不存在治愈PSC的方法,一部分出现肝衰竭或反复发生胆管炎的患者需要进行肝移植。PSC与恶性肿瘤风险增加相关,尤其是胆管癌,可能在12%的患者中发生。本章的主要目的是综述目前关于PSC的发病机制、临床方面及其相关恶性肿瘤的知识。